Stephen L. Chan

机构：Chinese University of Hong Kong, Prince of Wales Hospital, University of Hong Kong · ORCID：0000-0001-8998-5480

发表论文 723 篇 · 总被引 36157 次 · h-index 84

代表论文

• Cholangiocarcinoma 2026: status quo, unmet needs and priorities (2025 · Nature Reviews Gastroenterology & Hepatology · 被引 50)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 24)
• Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study. (2026 · Journal of Clinical Oncology · 被引 10)
• Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers (2025 · Liver International · 被引 9)
• Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma (2025 · Nature Communications · 被引 4)
• Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis (2025 · Liver Cancer · 被引 3)